“Delveinsight Business Research LLP”
DelveInsight’s “Dermatomyositis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dermatomyositis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Dermatomyositis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dermatomyositis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Dermatomyositis: An Overview
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of connective tissue disorders characterized by progressive muscle weakness. IIM is the umbrella term that includes dermatomyositis, polymyositis (PM), overlap myositis (OM), sporadic inclusion body myositis (IBM), and necrotizing autoimmune myopathy (NAM), also known as immune-mediated necrotizing myopathy (IMNM).
Dermatomyositis is a rare autoimmune disorder characterized by muscle inflammation (myositis) and skin inflammation (dermatitis). Proximal muscle weakness is a hallmark feature, affecting muscles close to the trunk, such as those in the thighs and upper arms, including heliotrope rash (purplish discoloration around the eyes), Gottron’s papules (reddish bumps on knuckles), and photosensitive rash on sun-exposed areas. It is a complex and heterogeneous condition that occurs in adults and even children, juvenile dermatomyositis (JDM). They share the hallmark features of pathognomic skin rash and muscle inflammation but are heterogeneous disorders with various additional features and complications.
The exact cause of dermatomyositis remains unknown, but it is thought to involve a combination of genetic susceptibility and environmental triggers. The diagnosis involves a combination of clinical evaluation, detection of characteristic physical findings, certain laboratory tests, and imaging studies. Key diagnostic criteria include muscle weakness, characteristic skin rash, elevated muscle enzymes, myositis-associated enzyme levels, electromyography, and muscle biopsy. Muscle biopsy is the most accurate test to confirm the diagnosis and to exclude other causes of muscle weakness or skin rash. However, choosing the right muscle for a biopsy is crucial to prevent a missing diagnosis.
Dermatomyositis Market Key Facts
-
Among the 7MM, the US had the largest market share for dermatomyositis, with a revenue of approximately USD 139.3 million in 2022.
-
Among EU4 and the UK countries, Germany accounted for the maximum market size of dermatomyositis in 2022, followed by the UK, while Spain occupied the bottom of the ladder.
-
Japan accounted for the second-largest market of dermatomyositis among the 7MM, with a revenue of approximately USD 30.8 million in 2022.
-
In 2022, the total diagnosed prevalent cases of dermatomyositis were estimated to be approximately 71,351 cases in the 7MM. Among these, nearly 9% were juvenile, while 91% were adult diagnosed prevalent cases of dermatomyositis.
-
In 2022, among the 7MM, the US accounted for the highest diagnosed prevalent cases of dermatomyositis, contributing nearly 54%, while Spain accounted for the least with nearly 4% of the total diagnosed prevalent cases.
-
In the US, there were approximately 38,266 diagnosed prevalent cases of dermatomyositis in 2022. These cases are expected to increase by 2032.
-
In 2022, Germany ranked first among EU4 and the UK, with approximately 5,280 diagnosed prevalent cases of dermatomyositis, followed by the UK and Italy with nearly 4,568 and 3,978 cases, respectively. The total cases in EU4 and the UK are expected to increase by 2032.
-
In EU4 and the UK, among the age-specific diagnosed prevalent cases of dermatomyositis, the age group 60–79 years accounted for the highest number of cases, with nearly 9,181 cases, while 0–17 had the least cases in 2022. These cases are expected to increase by 2032.
Dermatomyositis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dermatomyositis pipeline therapies. It also thoroughly assesses the Dermatomyositis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Dermatomyositis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Dermatomyositis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Dermatomyositis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Dermatomyositis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Dermatomyositis Epidemiology, Segmented as –
-
Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in the 7MM [2019–2032]
-
Total Diagnosed Prevalent Cases of Dermatomyositis (Adult and Juvenile) in the 7MM [2019–2032]
-
Age-specific Diagnosed Prevalent Cases of Dermatomyositis in the 7MM [2019–2032]
-
Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in the 7MM [2019–2032]
-
Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in the 7MM [2019–2032]
-
Comorbidities-specific Diagnosed Prevalent Cases of Dermatomyositis in the 7MM [2019–2032]
Dermatomyositis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Dermatomyositis market or expected to be launched during the study period. The analysis covers the Dermatomyositis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Dermatomyositis drugs based on their sale and market share.
The report also covers the Dermatomyositis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Dermatomyositis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Dermatomyositis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/dermatomyositis-market
Dermatomyositis Therapeutics Analysis
There is no cure for dermatomyositis; however, medication can reduce inflammation and vasculitis, invariably minimize symptomatology, and improve the patient’s quality of life. Several off-label medications, including corticosteroids, immunosuppressants, antimalarial drugs, antibiotics, and topical ointments, are combined to eliminate symptoms.
The current treatment landscape has several drawbacks, like most current therapies are off-label or generics, and there are only a few approved therapies including Octapharma’s OCTAGAM 10%, Mitsubishi Tanabe Pharma’s AZANIN, and Benesis Corporation’s (a subsidiary of Mitsubishi Tanabe Pharma) venoglobulin IH 5%.
However, novel therapies that target C5 complement, IFNβ1, FcRn, etc., are under development and are projected to enter the during the forecast period. The robust pipeline includes therapies like Priovant Therapeutics/Pfizer’s brepocitinib (PF-06700841), AstraZeneca’s ULTOMIRIS (ravulizumab) (ALXN1210), Argenx’s efgartigimod, Pfizer’s PF-06823859 (dazukibart) and CSL Behring’s HIZENTRA (IgPro20) and others. Currently, Corbus Pharmaceuticals is leading the therapeutics market with its Dermatomyositis drug candidates in the most advanced stage of clinical development.
Dermatomyositis Companies Actively Working in the Therapeutics Market Include
-
Corbus Pharmaceuticals
-
Kezar LifeSciences
-
Pfizer
-
CSL Behring
-
Viela Bio
-
Argenx
-
PAEAN Biotechnology
-
Alexion Pharmaceuticals
-
Priovant Therapeutics
And Many Others
Emerging and Marketed Dermatomyositis Therapies Covered in the Report Include:
-
Lenabasum: Corbus Pharmaceuticals
-
KZR-616: Kezar Life Sciences
-
Brepocitinib (PF-06700841): Priovant Therapeutics/Pfizer
-
ULTOMIRIS (ravulizumab/ALXN1210): AstraZeneca
-
PF-06823859 (anti-beta interferon): Pfizer
-
Efgartigimod: Argenx
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/dermatomyositis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dermatomyositis Competitive Intelligence Analysis
4. Dermatomyositis Market Overview at a Glance
5. Dermatomyositis Disease Background and Overview
6. Dermatomyositis Patient Journey
7. Dermatomyositis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Dermatomyositis Treatment Algorithm, Current Treatment, and Medical Practices
9. Dermatomyositis Unmet Needs
10. Key Endpoints of Dermatomyositis Treatment
11. Dermatomyositis Marketed Therapies
12. Dermatomyositis Emerging Drugs and Latest Therapeutic Advances
13. Dermatomyositis Seven Major Market Analysis
14. Attribute Analysis
15. Dermatomyositis Market Outlook (In US, EU5, and Japan)
16. Dermatomyositis Companies Active in the Market
17. Dermatomyositis Access and Reimbursement Overview
18. KOL Views on the Dermatomyositis Market
19. Dermatomyositis Market Drivers
20. Dermatomyositis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/dermatomyositis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Metastatic Uveal Melanoma Market
“Metastatic Uveal Melanoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Metastatic Uveal Melanoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Metastatic Uveal Melanoma market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Dermatomyositis Market Anticipating Remarkable Growth by 2032, Insights by DelveInsight | Corbus Pharma, Kezar LifeSciences, Pfizer, CSL, Viela Bio, Argenx, PAEAN Biotechnology, Alexion, Priovant
